Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Anthem Biosciences Ltd
Quarter-by-quarter operating performance
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 |
| Expenses + | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% |
| Other Income + | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% |
| Net Profit + | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 |
| EPS in Rs | 1.47 | 2.90 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 |
Financials of Anthem Biosciences Ltd
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 |
| Expenses + | 451 | 695 | 666 | 626 | 914 | 1,173 | 1,291 |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 | 834 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% | 39% |
| Other Income + | 21 | 37 | 49 | 139 | 63 | 85 | 131 |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 | 7 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 | 134 |
| Profit before tax | 121 | 366 | 546 | 497 | 477 | 657 | 824 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% | 28% |
| Net Profit + | 93 | 271 | 406 | 385 | 367 | 451 | 592 |
| EPS in Rs | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 | 10.54 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Anthem Biosciences Ltd
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 | 2,930 |
| Borrowings + | 159 | 100 | 35 | 126 | 239 | 113 | 53 |
| Other Liabilities + | 207 | 232 | 228 | 148 | 235 | 284 | 334 |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
| Fixed Assets + | 306 | 361 | 329 | 449 | 483 | 705 | 783 |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 | 264 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 | 1,007 |
| Other Assets + | 333 | 445 | 863 | 902 | 1,099 | 1,373 | 1,374 |
| Total Assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
Financials of Anthem Biosciences Ltd
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 166 | 278 | 333 | 306 | 140 | 418 | 844 |
| Cash from Investing Activity + | -109 | -196 | -205 | -376 | -221 | -152 | -702 |
| Cash from Financing Activity + | -48 | -63 | 181 | 64 | -77 | -134 | -40 |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | 133 | 103 |
| Free Cash Flow | 119 | 159 | 307 | 112 | -156 | 154 | 637 |
| CFO/OP | 116% | 85% | 81% | 98% | 51% | 86% | 126% |
Financials of Anthem Biosciences Ltd
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 | 101 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 | 56 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 | 34 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 | 124 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 | 207 |
| ROCE % | 55% | 51% | 28% | 24% | 28% | 30% |